PA
ADAP

Parallel Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Parallel Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250
Closed -$33 – 3621
2025
Q3 		$33 Hold
250
– – ﹤0.01% 3518
2025
Q2 		$60 Hold
250
– – ﹤0.01% 3482
2025
Q1 		$49 Hold
250
– – ﹤0.01% 3467
2024
Q4 		$135 Sell
250
-6,933
-97% -$5.05K ﹤0.01% 3418
2024
Q3 		$6.83K Buy
7,183
+6,933
+2,773% +$7.87K ﹤0.01% 2522
2024
Q2 		$244 Buy
+250
New +$274 ﹤0.01% 3181
2022
Q2 		– Sell
-1,853
Closed -$4K – 2945
2022
Q1 		$4K Buy
1,853
+1,041
+128% +$2.81K ﹤0.01% 2341
2021
Q4 		$3K Hold
812
– – ﹤0.01% 2538
2021
Q3 		$4K Buy
812
+97
+14% +$435 ﹤0.01% 2422
2021
Q2 		$3K Hold
715
– – ﹤0.01% 2422
2021
Q1 		$4K Sell
715
-190
-21% -$1.09K ﹤0.01% 2234
2020
Q4 		$5K Buy
905
+190
+27% +$1.03K ﹤0.01% 2006
2020
Q3 		$6K Hold
715
– – ﹤0.01% 1926
2020
Q2 		$7K Sell
715
-372
-34% -$2.34K ﹤0.01% 1826
2020
Q1 		$2K Buy
+1,087
New +$3.61K ﹤0.01% 2092
2019
Q3 		– Sell
-314
Closed -$734 – 2386
2019
Q2 		$1K Hold
314
– – ﹤0.01% 2162
2019
Q1 		$1K Hold
314
– – ﹤0.01% 2153
2018
Q4 		$1K Buy
+314
New +$2.32K ﹤0.01% 1965

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Parallel Advisors's ADAP Position: Q4 2025 in Review

Parallel Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 250 shares — an estimated $33 sold.

Parallel Advisors first reported a position in ADAP in Q4 2018 and held it in 18 quarters. The position peaked at $7K in Q2 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Parallel Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Parallel Advisors sold 250 Adaptimmune Therapeutics shares in Q4 2025, an estimated $33.
  • Parallel Advisors first reported a position in Adaptimmune Therapeutics in Q4 2018 and held it in 18 quarters.
  • Parallel Advisors's Adaptimmune Therapeutics position peaked at $7K in Q2 2020.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Parallel Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.